EVA1A facilitates glycolysis in esophageal squamous cell carcinoma to boost PLAU histone lactylation and dampen CD8 T cell activity.

Background: Endogenous retrovirus group E member 1 (EVA1A) is expressed in various normal tissues and plays a role in tumor development. However, its function in esophageal squamous cell carcinoma (ESCC) and immune regulation remains unclear.

Research Design And Methods: Bioinformatics, clinical samples, and in vivo/in vitro experiments were used to evaluate EVA1A expression and function.

Impact of first-line chemoimmunotherapy with or without radiotherapy on the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma: a multicenter, real-world, retrospective cohort study from China (NCT06478355).

Background: Chemotherapy combined with immunotherapy has already become the standard first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC), whereas there are no satisfying overall survival (OS) and progression-free survival (PFS). This research aims to evaluate whether first-line chemoimmunotherapy combined with radiotherapy (RT) improves outcomes and safety in patients who suffer from locally advanced and metastatic ESCC.

Methods: A total of 664 patients who suffer from locally advanced or metastatic ESCC going through first-line chemoimmunotherapy with or without radiotherapy at China's 11 large cancer centers from Jan.

Clinicopathologic characteristics and outcome of gastric-type endocervical adenocarcinoma: a single-center retrospective study.

Background: This study investigated the clinical and pathological characteristics of gastric-type endocervical adenocarcinoma (G-EAC) to advance the early diagnosis and treatment of this disease.

Methods: The diagnosis, treatment, follow-up, pathological morphology, immunohistochemical characteristics and other data of 15 patients of G-EAC visiting our hospital from December 2016 to March 2024 were retrospectively analyzed, and the relevant literature was discussed.

Results: The mean age of participants was 45.

Telaprevir attenuates caspase-11-dependent pyroptosis in mouse heart following ischemia/reperfusion via inhibition of MALT1/TRAF6 pathway.

Pyroptosis is one of the major forms of cardiomyocyte death following ischemia/reperfusion (I/R). Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1)/Tumor necrosis factor receptor associated factor 6 (TRAF6) pathway is involved in cardiomyocyte pyroptosis in mouse heart following I/R, and telaprevir, a hepatitis C virus protease inhibitor, has been predicted as a potential inhibitor of MALT1. This study aims to explore the effect of telaprevir on I/R-induced cardiomyocyte pyroptosis.

Risk factors and bacterial spectrum postoperative infections after esophageal tumor surgery in patients aged ≥60 years.

Purpose: Patients undergoing esophageal tumor surgery (ETS) are at increased risk of postoperative infections (PI), particularly those aged ≥60 years. To improve perioperative safety and outcomes in this population, this study aimed to investigate the bacterial spectrum and identify risk factors associated with PI following ETS.

Methods: A total of 747 patients who underwent radical esophagectomy between January and December 2021 were included in this retrospective analysis.

Combined detection of P53, Ki67, P504S, and IMP3: Diagnostic implications for gastric cancer and precursor lesions.

Background: Differential diagnosis among atypical hyperplasia (AH) (including reparative hyperplasia and intestinal metaplasia), low-grade dysplasia (LGD), high-grade dysplasia (HGD), and adenocarcinoma (AC) in gastric mucosal biopsies is challenging due to histomorphological overlaps, variability in pathological diagnosis consistency, and limited reproducibility.

Aim: To evaluate the diagnostic utility of P53, Ki67, P504S, and IMP3 in gastric cancer and its precancerous lesions, focusing on their effectiveness in distinguishing AH, LGD, HGD, and AC.

Methods: From January 2018 to September 2020, a total of 185 gastric mucosal biopsy specimens were analyzed according to the pathological diagnostic criteria outlined in the World Health Organization Classification of Digestive System Tumors (2019).

Efficacy, Safety, and Cost-Effectiveness Analysis of Ceftazidime-Avibactam versus Polymyxin B in the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections: A Target Trial Emulation.

Introduction: Treatment options for carbapenem-resistant Enterobacteriaceae (CRE) infections are limited, with polymyxin B (PMB) and ceftazidime-avibactam (CZA) being among the available choices. However, research on these options is scarce and significantly heterogeneous. This study aims to analyze the efficacy, safety, and cost-effectiveness of PMB and CZA within a standardized target trial emulation (TTE) framework.

Harnessing Calmodulin-Related Genes to Build a Prognostic Model in Esophageal Squamous Cell Carcinoma for a Comprehensive Analysis of Single-Cell Immune Characteristics and Drug Efficacy.

Calmodulin (CALM) has a bearing on the prognosis of various cancers. However, the prognostic value of CALM in esophageal squamous cell carcinoma (ESCC) remains unelucidated. Differentially expressed genes (DEGs) were screened between normal and tumor groups of TCGA-ESCC sets.

FOXA1 Targets NEK2 to Mediate Cisplatin Resistance in Lung Adenocarcinoma Cells by Activating DNA Damage Repair.

Lung adenocarcinoma (LUAD) is one of the main causes of death in cancer patients, as its hidden course is difficult to uncover, resulting in many patients being diagnosed as advanced. Late-stage LUAD patients are prone to develop resistance to cisplatin. This study aims to explore the potential molecular regulatory mechanism of NEK2 on cisplatin resistance in LUAD cells.

CALCR interaction with ANTXR1 drives gastric tumor growth and metastasis via AKT signaling pathway.

This study investigates the role of CALCR, a G-protein-coupled receptor, in gastric cancer (GC) progression and its interaction with ANTXR1. A total of 121 patients with gastric cancer were enrolled from the Department of General Surgery, Anyang Tumor Hospital, Anyang City, Henan Province, China. 218 tumor tissues and corresponding para-carcinoma tissues were collected from 109 patients, while adjacent tissues were retained from the remaining 12 cases.

Molecular classification of hormone receptor-positive /HER2-positive breast cancer reveals potential neoadjuvant therapeutic strategies.

Significant heterogeneity exists in hormone receptor (HR)-positive/HER2-positive (HR/HER2) breast cancer, contributing to suboptimal pathological complete response rates with conventional neoadjuvant treatment regimens. Overcoming this challenge requires precise molecular classification, which is pivotal for the development of targeted therapies. We conducted molecular typing on a cohort of 211 patients with HR/HER2 breast cancer and performed a comprehensive analysis of the efficacy of various neoadjuvant treatment regimens.

Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab to chemotherapy plus trastuzumab as neoadjuvant therapy.

Background: Human epidermal growth factor receptor 2(HER-2) is the most prominent therapeutic target for gastric (G)/gastroesophageal junction (GEJ) cancer. Guidelines recommend its use for treating G/GEJ cancers. However, targeted therapy did not significantly improve survival outcomes compared to those with neoadjuvant therapy.

Does the Presence of Ductal Carcinoma in situ Affect Prognostic Outcomes After Neoadjuvant Therapy in Invasive Ductal Carcinoma of the Breast?

Aims: The presence of ductal carcinoma in situ (DCIS) alongside invasive ductal carcinoma (IDC) of the breast is common in clinical practice and affects clinical outcomes and treatment strategies. This study aimed to compare the clinicopathological characteristics and prognosis of patients with IDC coexisting with DCIS versus pure IDC after neoadjuvant therapy (NAT) and to explore the risk factors for residual DCIS following NAT.

Material And Methods: Patients with Stage II-III IDC who underwent NAT followed by radical surgery between January 2015 and December 2022 were included.

A retrospective multicenter study on the efficacy and safety of disitamab vedotin monotherapy versus combination with anti-PD-1 immunotherapy in advanced gastric cancer.

Novel therapeutic agents including disitamab vedotin (RC48, an antibody-drug conjugate) and immune-checkpoint inhibitors (e.g., PD-1 inhibitors) have provided new hope as an advanced gastric-cancer (GC) treatment.

Prediction of the Survival Status, Immunotherapy Response, and Medication of Lung Adenocarcinoma Patients Based on Hypoxia- and Apoptosis-Related Genes.

To predict patient survival prognosis, we aimed to establish a novel set of gene features associated with hypoxia and apoptosis. RNA-seq and clinical data of LUAD were sourced from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, while hypoxia and apoptosis-related genes were obtained from the Molecular Signatures Database (MsigDB). A 13-gene-prognostic model incorporating hypoxia and apoptosis genes was developed using univariate/multivariate Cox regression, Nonnegative Matrix Factorization (NMF) clustering, and LASSO regression.

Fusobacterium nucleatum promotes PD-L1 expression in cancer cells to evade CD8 T cell killing in breast cancer.

Background: A significant percentage of cancer-related fatalities are caused by breast cancer (BC). Fusobacterium nucleatum (Fn) is a common Gram-negative anaerobic bacterium found in various inflammatory diseases, and there are also reports suggesting its involvement in cancer progression. This study discussed molecular mechanisms of Fn-induced immune escape in BC cells.

Establishment and validation of the prognostic risk model based on the anoikis-related genes in esophageal squamous cell carcinoma.

Background: Esophageal squamous cell carcinoma (ESCC) is a malignant condition in humans. Anoikis-related genes (ARGs) are crucial to cancer progression. Therefore, more studies on the relationship between ARGs and ESCC are warranted.

Thoracic Radiotherapy Improves the Survival in Patients With -Mutated Oligo-Organ Metastatic Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial.

Purpose: This multicenter, randomized, phase III clinical trial (Northern Radiation Oncology Group of China-002) focused on patients with oligo-organ metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor () mutations. We aimed to investigate whether first-line concurrent thoracic radiotherapy (TRT) and EGFR-tyrosine kinase inhibitors (TKIs), compared with TKIs alone, could achieve better survival.

Materials And Methods: The patients in the TKI plus TRT group received 60 Gy to primary lung tumor and positive regional lymph nodes.

Mechanism of LMNB1 activating GPR84 through JAK-STAT pathway to mediate M2 macrophage polarization in lung cancer.

Background: It is reported that G protein-coupled receptor 84 (GPR84) can participate in inflammation and immune regulation to repress anti-tumor responses. However, the function of GPR84 in lung cancer (LC) and its potential molecular mechanisms are still largely unknown.

Methods: Bioinformatics and molecular experiments were employed to assess the expression of GPR84 in LC.

circRNA6448-14/miR-455-3p/OTUB2 axis stimulates glycolysis and stemness of esophageal squamous cell carcinoma.

Background: Esophageal squamous cell carcinoma (ESCC) is a gastrointestinal malignancy with high incidence. This study aimed to reveal the complete circRNA-miRNA-mRNA regulatory network in ESCC and validate its function mechanism.

Method: Expression of OTU Domain-Containing Ubiquitin Aldehyde-Binding Protein 2 (OTUB2) in ESCC was analyzed by bioinformatics to find the binding sites between circRNA6448-14 and miR-455-3p, as well as miR-455-3p and OTUB2.

Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial.

Purpose: This phase 3 trial aimed to compare the efficacy and safety of capecitabine or capecitabine plus oxaliplatin (XELOX) with those of fluorouracil plus cisplatin (PF) in definitive concurrent chemoradiotherapy (DCRT) for inoperable locally advanced esophageal squamous cell carcinoma (ESCC).

Methods: Patients were randomly assigned to receive two cycles of capecitabine, XELOX, or PF along with concurrent intensity-modulated radiation therapy. Patients in each arm were again randomly assigned to receive two cycles of consolidation chemotherapy or not.

Screening of lung cancer serum biomarkers based on Boruta-shap and RFC-RFECV algorithms.

Objective: This study aimed to identify a set of serum miRNAs as potential biomarkers for lung cancer diagnosis using algorithmic approaches.

Methods: Serum miRNA expression data from lung cancer patients and non-tumor controls were obtained. The top six miRNAs were selected using Boruta-shap and RFC-RFECV algorithms.